Search all trials

Find therapies in clinical trials near you – page 3

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Hormone receptor positive HER2 negative breast cancer+2

Not yet recruiting

Registered drug

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Letrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+2

Not yet recruiting

Registered drugNo placebo

Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study on Improving Quality of Life for Early Breast Cancer Patients Using Duloxetine and Furosemide to Manage Endocrine Therapy-Related Pain

Registered drugNo placebo

Cyprus

Participants:18–64 years · 65+ years
Substances:Duloxetine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not yet recruiting

Registered drugNo placebo

Study on Alpelisib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer

Registered drugNo placebo

Croatia

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

InvestigationalNo placebo

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Registered drugNo placebo

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+2

Not recruiting

Registered drugNo placebo

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+3

Not recruiting

InvestigationalNo placebo

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:ZELENECTIDE PEVEDOTIN

Contact Research Centre

Find therapies in clinical trials near you – page 3

62 trials match your criteria

Hormone receptor positive HER2 negative breast cancer+2

Efficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Hormone receptor positive HER2 negative breast cancer+2

Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

Hormone receptor positive HER2 negative breast cancer

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Hormone receptor positive HER2 negative breast cancer

Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

Hormone receptor positive HER2 negative breast cancer

Study on Improving Quality of Life for Early Breast Cancer Patients Using Duloxetine and Furosemide to Manage Endocrine Therapy-Related Pain

Hormone receptor positive HER2 negative breast cancer+1

Study on Alpelisib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer

Hormone receptor positive HER2 negative breast cancer

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

Hormone receptor positive HER2 negative breast cancer+1

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Hormone receptor positive HER2 negative breast cancer+2

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Hormone receptor positive HER2 negative breast cancer

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Hormone receptor positive HER2 negative breast cancer+3

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.